Physician profile
Hari B Ancha
NPI 1992755128
$5,335.37
in general payments reported to CMS, 2019-2025
37 companies · $1,145 in 2025
The $1,145 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $775 · 2020: $275 · 2021: $486 · 2022: $1,067 · 2023: $614 · 2024: $973 · 2025: $1,145.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,716 · Education: $16.42.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,715.78 |
| Education | $16.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,090.42 | 2019-2025 | Linzess, Viberzi |
| Celgene Corporation | $428.58 | 2021-2024 | Zeposia |
| E.R. Squibb & Sons, L.L.C. | $332.40 | 2021-2023 | Zeposia |
| Genzyme Corporation | $327.21 | 2023-2025 | |
| Phathom Pharmaceuticals, INC. | $311.14 | 2024-2025 | Voquezna |
| Enterra Medical, INC. | $276.96 | 2024-2025 | |
| Gilead Sciences, INC. | $241.70 | 2019-2022 | |
| Ipsen Biopharmaceuticals, INC | $212.11 | 2025 | Iqirvo |
| Lilly USA, LLC | $201.82 | 2024-2025 | Omvoh |
| Merck Sharp & Dohme LLC | $172.64 | 2021-2024 | Dificid |
| Intercept Pharmaceuticals, INC. | $169.00 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $167.27 | 2019-2025 | Eohilia, Gattex |
| Pfizer INC. | $166.28 | 2019-2023 | |
| Boston Scientific Corporation | $149.35 | 2025 | Axonics |
| Ferring Pharmaceuticals INC. | $124.44 | 2022-2024 | Rebyota |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shionogi INC | $119.87 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $115.26 | 2023-2024 | Dupixent |
| Allergan, INC. | $78.79 | 2019-2020 | |
| Medtronic, INC. | $74.66 | 2021-2024 | Interstim, Gi Genius |
| Aimmune Therapeutics, INC. | $64.18 | 2025 | Zenpep |
| Janssen Biotech, INC. | $60.12 | 2019-2025 | Tremfya |
| Ardelyx, INC. | $53.19 | 2023-2025 | Ibsrela |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $47.51 | 2019-2021 | |
| Organon LLC | $36.29 | 2023-2024 | Hadlima, Renflexis |
| Nestle Healthcare Nutrition INC. | $33.16 | 2021-2023 | |
| Madrigal Pharmaceuticals | $32.41 | 2024-2025 | Rezdiffra, Resmetirom |
| Cook Medical LLC | $30.01 | 2022 | |
| Erbe USA INC | $30.00 | 2020 | |
| Ucb, INC. | $25.61 | 2019 | |
| Alfasigma USA, INC. | $24.97 | 2021 | |
| Redhill Biopharma INC. | $24.24 | 2021 | |
| Astellas Pharma US INC | $23.02 | 2024 | Vyloy |
| Daiichi Sankyo INC. | $22.55 | 2022 | |
| Endogastric Solutions, INC | $20.88 | 2019 | |
| Amgen INC. | $16.73 | 2025 | Uplizna |
| Novo Nordisk INC | $15.50 | 2025 | Wegovy |
| Johnson & Johnson Health Care Systems INC. | $15.10 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hari Ancha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.